亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

海南滿方園醫藥化工有限公司  

研發化學藥品 醫藥原料 中間體 化工原料

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:吳伯炯
  • 電話:0898-66518050
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 咪唑并[1,2-A]吡嗪-2-甲酸乙酯
咪唑并[1,2-A]吡嗪-2-甲酸乙酯
單價 面議對比
詢價 暫無
發貨 海南海口市付款后3天內
品牌 咪唑并[1,2-A]吡嗪-2-甲酸乙酯查收:77112-52-8
過期 長期有效
更新 2022-03-15 09:14
 
詳細信息

英文名稱:ETHYLIMIDAZO[1,2-A]PYRAZINE-2-CARBOXYLATE

英文同義詞:WCIUYUMPQYSUSD-GBCQHVBFSA-N;ETHYLIMIDAZO[1,2-A]PYRAZINE-2-CARBOXYLATE;2-imidazo[1,2-a]pyChemicalbookrazinecarboxylicacidethylester;IMIDAZO[1,2-A]PYRAZINE-2-CARBOXYLICACIDETHYLESTER

中文名稱:咪唑并[1,2-A]吡嗪-2-甲酸乙酯中文同義詞:咪唑并[1,2-A]吡嗪-2-甲酸乙酯;咪唑并【1,2-A】吡嗪-2-甲酸乙酯250MG

CBNumber:CB2778796      分子式:C9H9N3O2       分子量:191.19

©2025 海南滿方園醫藥化工有限公司 版權所有   技術支持:化工網   訪問量:16692  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |